树冠增长公司以1.25亿美元的价格购买MTL大麻,以促进其大麻医疗业务和削减成本。 Canopy Growth buys MTL Cannabis for $125M to boost its medical cannabis business and cut costs.

树冠增长同意在1.25亿美元的交易中购买MTL大麻,向MTL股东提供0.32个树冠股份和1.44美元现金,这是MTL最近平均价格的45%的溢价。 Canopy Growth has agreed to acquire MTL Cannabis in a $125 million deal, offering MTL shareholders 0.32 Canopy shares and $0.144 cash per share, a 45% premium to MTL’s recent average price. 法院批准的交易,在监管和股东批准之前,预计将在2026年2月前结束。 The court-approved transaction, pending regulatory and shareholder approvals, is expected to close before February 2026. 收购的目的是通过增加MTL的病人网络、诊所和在线平台、扩大其供应能力和支持其获利途径,加强Canopy的大麻医疗存在。 The acquisition aims to strengthen Canopy’s medical cannabis presence by adding MTL’s patient network, clinics, and online platform, expanding its supply capabilities and supporting its path to profitability. Canopy预计每年在18个月内节省1 000万美元的费用。 Canopy anticipates $10 million in annual cost savings within 18 months.